Baker McKenzie is advising C-Lab International Limited, a wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharmaceutical"), on its acquisition of SOFTHALE NV (“Softhale”) for USD 110 million and additional payments related to regulatory and commercial milestones.
Sino Biopharmaceutical, together with its subsidiaries, is a leading, innovative research and development (“R&D”) driven pharmaceutical conglomerate in China. Its business encompasses a fully integrated chain in pharmaceutical products, which covers an array of innovative R&D platforms and pipeline, a lineup of intelligent manufacturing and a strong sales infrastructure.
Softhale is a privately-owned Belgian company focused on the development of products for the treatment of respiratory diseases.
The Baker McKenzie core team includes: Derek Poon (Private Equity/ M&A Partner, Hong Kong), Dr. Thorsten Seidel (M&A Partner, Berlin), Dominique Maes (Private Equity/M&A Partner, Brussels), Kim Stas (Private Equity/M&A Counsel, Brussels) and Bruno Schroé (Private Equity/M&A Associate, Brussels).
For further details about the transaction, please refer to Sino Biopharmaceutical’s press release.